血清多肽组学在恶性肿瘤中的研究进展

Research progress on serum peptidomics in malignant tumors

恶性肿瘤严重危害患者的身心健康,早期发现、早期诊断和早期治疗是提高其疗效的关键。血清作为微创检查的常规样本来源,获得普遍认可。多肽具有结构简单、相对分子质量低于1.0×104、特异性强和易于合成等特点,血清多肽组学作为蛋白组学的重要补充,在临床样本中的多肽检测正引起学术界和医药界的高度重视。本文就多肽组学与蛋白质组学的关系、多肽组学在血清中的应用、血清多肽组学在恶性肿瘤中的应用、血清多肽组学在口腔癌中的应用、血清多肽组学存在的问题等研究进展作一综述。

Malignant tumors have been a hazard factor to the mental and physical health of human beings. The key to improve curing effectiveness rely on early detection, early diagnosis and early treatment. It is generally recognized to use serum as a common measure to have a minimally invasive examination. Being a complementary method of proteomies, serum peptidomics maintain a character of simple structure, less than 1.0xl0^4 molecular weight, high specialty and easy for synthetize, which arouse the academic and medicine attention in clinical proteomies at present. This article intends to review the research progression of serum peptidomics on hiomarkers dis- covery in malignant tumors.